Insights

Emerging Biopharma Focus Position Synteract as a leading CRO dedicated to the emerging biopharma segment with a track record across oncology, dermatology, rare diseases, pediatrics, vaccines, and neuroscience to target biotech startups and mid-stage biopharma companies expanding their clinical programs.

Global Clinic Footprint Leverage Synteract's extensive global reach with studies conducted on six continents and in over 62 countries to offer multinational trial capabilities, site feasibility, and regulatory readiness for global phase I-IV programs.

Strategic Growth Partners Capitalize on ownership changes and growth momentum from recent partnerships and leadership hires to position Synteract as a stable, growth-oriented partner for biotech firms seeking scale, operational improvements, and commercial expansion.

Post-Mergers & Acquisitions Target companies undergoing consolidation or portfolio expansion, highlighting Synteract’s integrations such as Clindata and KinderPharm assets, and dermatology or pediatric development capabilities gained through mergers and acquisitions.

Financial Fit & Collaboration Communicate a compelling value proposition for mid-market CRO opportunities with annual revenue ranges aligning to Synteract’s size, emphasizing cost-effective, full-service Phase I-IV capabilities and potential for co-development or strategic collaborations with growing biopharma entities.

Similar companies to Synteract

Synteract Tech Stack

Synteract uses 8 technology products and services including Google Conversion Tracking, Crazy Egg, Hotjar, and more. Explore Synteract's tech stack below.

  • Google Conversion Tracking
    Advertising Networks
  • Analytics
  • Analytics
  • RackSpace Cloud
    Data Management Platforms
  • Marketing
  • reCAPTCHA
    Security
  • Bootstrap
    UI Frameworks
  • Google Analytics
    Web Analytics

Media & News

Synteract's Email Address Formats

Synteract uses at least 7 email formats:
Synteract Email FormatsExamplePercentage
First.Last@synteract.comJohn.Doe@synteract.com
82%
FLast@synteract.comJDoe@synteract.com
13%
Last.First@synteract.comDoe.John@synteract.com
3%
FirstLast@synteract.comJohnDoe@synteract.com
2%
First.Last@synteracthcr.comJohn.Doe@synteracthcr.com
97%
FLast@synteracthcr.comJDoe@synteracthcr.com
2%
First@synteracthcr.comJohn@synteracthcr.com
1%

Frequently Asked Questions

What is Synteract's phone number?

Minus sign iconPlus sign icon
You can contact Synteract's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Synteract's official website and social media links?

Minus sign iconPlus sign icon
Synteract's official website is synteract.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Synteract generate?

Minus sign iconPlus sign icon
As of October 2026, Synteract's annual revenue is estimated to be $50M - $100M.

What is Synteract's SIC code and NAICS code?

Minus sign iconPlus sign icon
Synteract's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Synteract have currently?

Minus sign iconPlus sign icon
As of October 2026, Synteract has approximately 160 employees across 3 continents, including North America, Europe and Africa. Key team members include Vp Strategic Development, Oncology: C. H., President: F. J. J. H. and President: M. K. Explore Synteract's employee directory with LeadIQ.

What industry does Synteract belong to?

Minus sign iconPlus sign icon
Synteract operates in the Biotechnology Research industry.

What technology does Synteract use?

Minus sign iconPlus sign icon
Synteract's tech stack includes Google Conversion Tracking, Crazy Egg, Hotjar, RackSpace Cloud, Pardot, reCAPTCHA, Bootstrap and Google Analytics.

What is Synteract's email format?

Minus sign iconPlus sign icon
Synteract's email format typically follows the pattern of First.Last@synteract.com. Find more Synteract email formats with LeadIQ.

How much funding has Synteract raised to date?

Minus sign iconPlus sign icon
As of October 2026, Synteract has raised $3M in funding. The last funding round occurred on Feb 18, 2014 for $3M.
Synteract logo

Synteract

Biotechnology ResearchNorth Carolina, United States51-200 Employees

Synteract is a biotechnology research company that operates as a full-service contract research organization and is part of Syneos Health. It focuses on the emerging biopharma segment and supports biotech and pharmaceutical companies across all phases of drug development, with deep expertise in oncology, dermatology, general medicine, infectious disease and vaccines, neuroscience, pediatrics, and rare and orphan diseases. The company has conducted nearly 4,000 studies across six continents in more than 62 countries. Synteract is headquartered in Morrisville, North Carolina, at 430 Davis Drive, Suite 500, and employs between 51 and 200 people. The corporate history includes being acquired by Amulet Capital Partners LP in May 2016, with Steve Powell joining as CEO in 2017, and growth through acquisitions of Clindata (February 2020) and KinderPharm (November 2018) and a merger with Cu-Tech in August 2018, as well as a partnership with Amulet in October 2020.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $3M

    Synteract has raised a total of $3M of funding over 3 rounds. Their latest funding round was raised on Feb 18, 2014 in the amount of $3M as a Private Equity.

  • $50M - $100M

    Synteract's revenue is estimated to be in the range of $50M - $100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.